Leronlimab

Phase 3Monoclonal antibody

CCytoDyn, Inc.

Leronlimab is one of 104 small molecule programs targeting Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

PneumoniaActive, not recruiting

Breast CancerActive, not recruiting

COVID-19Active, not recruiting

HepatitisPhase 2

Active, not recruiting

PneumoniaPhase 3

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Leronlimab

CCytoDyn, Inc.

Phase 3

1 2

Trodelvy

Gilead

Preclinical

37 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

MS Contin

Merck & Co.

Preclinical

2 5

Voltaren

Novartis

Preclinical

1 6

Zolymbus

AbbVie

Preclinical

1 7

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 9

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 10

Chirocaine

PPurdue Pharma LP

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Bevacizumab

NCT06699836

Clinical

Trials by Indication[1]

COVID-194 trials

Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation

Suspended·HHospital Israelita Albert Einstein·Phase 3·NCT04901689·316 enrolled

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

Completed·CCytoDyn, Inc.·Phase 2·NCT04343651·86 enrolled

Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

Completed·CCytoDyn, Inc.·Phase 2·NCT04678830·56 enrolled

Show 1 more trial

Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

Completed·CCytoDyn, Inc.·Phase 2·NCT04347239·484 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

Completed·CCytoDyn, Inc.·Phase 2·NCT04504942·16 enrolled

Pneumonia1 trial

Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia

Suspended·HHospital Israelita Albert Einstein·Phase 3·NCT04901676·612 enrolled

Breast Cancer1 trial

A Compassionate Use Study of Leronlimab in Breast Cancer

No longer available·CCytoDyn, Inc.··NCT04313075

Carboplatin1 trial

Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

Terminated·CCytoDyn, Inc.·Phase 1/2·NCT03838367·10 enrolled

2 more indications

Hepatitis1 trial

Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis

Completed·CCytoDyn, Inc.·Phase 2·NCT04521114·87 enrolled

Bevacizumab1 trial

A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC

Recruiting·CCytoDyn, Inc.·Phase 2·NCT06699836·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Leronlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Leronlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Leronlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CytoDyn, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: CCytoDyn, Inc.

Leronlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

COVID-194 trials

Locally Advanced or Metastatic Solid Tumors1 trial

Pneumonia1 trial

Breast Cancer1 trial

Carboplatin1 trial

Hepatitis1 trial

Bevacizumab1 trial

References

Drug Info

Quick Facts

Related News